Haibiao Xie

Haibiao Xie

Auto-generated profile, based on publicly available information

Haibiao Xie

Department of Urology, Peking University First Hospital, Beijing, Beijing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HXHaibiao Xie
Haibiao Xie
JZJin Zhou
Jin Zhou
XLXijuan Liu
Xijuan Liu
YXYawei Xu
Yawei Xu
AHAustin J. Hepperla
Austin J. Hepperla
QZQING ZHANG
QING ZHANG
Clear cell renal cell carcinoma (ccRCC) is characterized by the loss of tumor suppressor Von Hippel Lindau (VHL) function. VHL is the component of an E3 ligase complex that promotes the ubiquitination and degradation of hypoxia inducible factor α (HIF-α) (including HIF1α and HIF2α) and Zinc Fingers And Homeoboxes 2 (ZHX2). Our recent research showed that ZHX2 contributed to ccRCC tumorigenesis in a HIF-independent manner. However, it is still unknown whether ZHX2 could be modified through deubiquitination even in the absence of pVHL. Here, we performed a deubiquitinase (DUB) complementary DNA (cDNA) library binding screen and identified USP13 as a DUB that bound ZHX2 and promoted ZHX2 deubiquitination. As a result, USP13 promoted ZHX2 protein stability in an enzymatically dependent manner, and depletion of USP13 led to ZHX2 down-regulation in ccRCC. Functionally,USP13depletion led to decreased cell proliferation measured by two-dimensional (2D) colony formation and three-dimensional (3D) anchorage-independent growth. Furthermore, USP13 was essential for ccRCC tumor growth in vivo, and the effect was partially mediated by its regulation on ZHX2. Our findings support that USP13 may be a key effector in ccRCC tumorigenesis.

1 October 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
HXHaibiao Xie
Haibiao Xie
BMBo Ma
Bo Ma
QGQunjun Gao
Qunjun Gao
HZHengji Zhan
Hengji Zhan
YLYuchen Liu
Yuchen Liu
WHWeiRen Huang
WeiRen Huang

5 December 2018 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
QZQun Zhou
Qun Zhou
HZHengji Zhan
Hengji Zhan
XLXinhui Liao
Xinhui Liao
LFLan Fang
Lan Fang
YLYuhan Liu
Yuhan Liu
YLYuchen Liu
Yuchen Liu
With the development of synthetic biology, synthetic gene circuits have shown great applied potential in medicine, biology, and as commodity chemicals. An ultimate challenge in the construction of gene circuits is the lack of effective, programmable, secure and sequence‐specific gene editing tools. The clustered regularly interspaced short palindromic repeat (CRISPR) system, a CRISPR‐associated RNA‐guided endonuclease Cas9 (CRISPR‐associated protein 9)‐targeted genome editing tool, has recently been applied in engineering gene circuits for its unique properties‐operability, high efficiency and programmability. The traditional single‐targeted therapy cannot effectively distinguish tumour cells from normal cells, and gene therapy for single targets has poor anti‐tumour effects, which severely limits the application of gene therapy. Currently, the design of gene circuits using tumour‐specific targets based on CRISPR/Cas systems provides a new way for precision cancer therapy. Hence, the application of intelligentized gene circuits based on CRISPR technology effectively guarantees the safety, efficiency and specificity of cancer therapy. Here, we assessed the use of synthetic gene circuits and if the CRISPR system could be used, especially artificial switch‐inducible Cas9, to more effectively target and treat tumour cells. Moreover, we also discussed recent advances, prospectives and underlying challenges in CRISPR‐based gene circuit development.

16 December 2021 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
KZKenan Zhang
Kenan Zhang
JQJianhui Qiu
Jianhui Qiu
WYWuping Yang
Wuping Yang
KMKaifang Ma
Kaifang Ma
LLLei Li
Lei Li
KGKan Gong
Kan Gong
Background Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic tumour syndrome with poor prognosis. The clinical manifestation was found to be more serious in affected offspring of patients with VHL disease, but the risk factors and survival for them have never been reported before. We aimed to explore how these patients were influenced by genetic and clinical factors. Methods In this retrospective study, we collected 372 affected offspring of VHL patients from 118 unrelated VHL families. Patients were stratified into different groups based on sets of variables. The age-related risk, overall survival and central nervous systemhaemangioblastoma (CHB)-specific survival were analysed between different groups using Kaplan-Meier survival analysis and Cox regression analysis. Results The estimated median life expectancy and median age of onset for affected offspring of VHL patients were 66 years and 28 years, respectively. The later generation and patients with mutations in exon 3 had an earlier onset age. The first presenting symptom was the only independent risk factor influencing overall survival and CHB-specific survival. Patients that the first presenting symptom is central nervous system (CNS) significantly had a lower life expectancy both in overall survival and CHB-specific survival analysis than abdominal lesions group. Conclusion This study indicated that affected offspring of VHL patients with CNS as the first presenting symptom was an independent risk factor for overall survival and CHB-specific survival. Generation and mutation region only had an effect on the onset age, which is helpful to clinical decision-making and generate a more precise surveillance protocol.

17 April 2020 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
HXHaibiao Xie
Haibiao Xie
KMKaifang Ma
Kaifang Ma
JZJiufeng Zhang
Jiufeng Zhang
BHBaoan Hong
Baoan Hong
JZJingcheng Zhou
Jingcheng Zhou
LCLin Cai
Lin Cai
Background: Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic tumour syndrome resulting from mutations in the VHL gene lineage, and its prognosis is generally poor. This study aimed to provide a more valuable genotype–phenotype correlation based on the Elongin C binding site in VHL disease. Methods: This study included 553 patients (194 families) who were diagnosed with VHL disease in our centre from September 2010 to February 2019. According to the type of gene mutation, the patients were divided into the Elongin C binding site missense mutation (EM) group, the non-Elongin C binding site missense mutation (nEM) group and the truncation mutation (TR) group. We analysed and compared the age-related tumour risk and prognosis of the three groups. Results: A total of 14 new intragenic mutations were found in this cohort. The age-related risk of central nervous system haemangioblastoma (CHB) and pancreatic tumour in the EM group was lower than in the combined nEM-TR group, while the corresponding risk of pheochromocytoma (PHEO) was higher. Additionally, the prognoses of EM and nEM-TR were analysed. The median survival period in the EM group was longer than that in the nEM-TR group, and both the total survival and the CHB-specific survival of the EM group were better than those of the nEM-TR group. Conclusion: In conclusion, our study demonstrated that the EM was an independent risk factor for PHEO. The EM is also an independent protective factor for CHB age-related risk, overall survival and CHB-specific survival in VHL disease. This modified genotype–phenotype correlation integrates gene mutation, the Elongin B binding site, and phenotypic diversity and provides a reference for clinical diagnosis.

1 July 2017 in Minerva Medica
Verified
Journal Article
Closed access
ZCZhicong Chen
Zhicong Chen
HXHaibiao Xie
Haibiao Xie
YZYucheng Zhong
Yucheng Zhong
YLYuchen Liu
Yuchen Liu
WHWeiren Huang
Weiren Huang
Article: Role of nuclear paraspeckle assembly transcript 1 as a common molecular marker for prognosis in various cancers - Minerva Medica 2017 October;108(5):477-9 - Minerva Medica - Journals